Showing results (81-90 of 179) with videos related to

Sort By:
Pageof 18
The Oncologist|August 11, 2020
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular CancerRichard Kim, Elaine Tan, Emily Wang, et al.
Journal of Liver Cancer|December 16, 2025
A rare case of IgG4-related sclerosing cholangitis followed by rapid subsequent diagnosis of cholangiocarcinomaGordon Hong, Amber Hussain, Eduardo Thadeu de Oliveira Correia, et al.
Clinical Colorectal Cancer|June 11, 2019
Novel Prognostic Factors in Resected Small Bowel AdenocarcinomaBrandon M Huffman, Zhaohui Jin, Siddhartha Yadav, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel CombinationAmr Mohamed, Asfar S Azmi, Sylvia L Asa, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 30, 2018
Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinomaAnuhya Kommalapati, Sri Harsha Tella, Gaurav Goyal, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 20, 2020
Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survivalSri Harsha Tella, Anuhya Kommalapati, Siddhartha Yadav, et al.
Journal of Gastrointestinal Oncology|April 30, 2019
Local excision for patients with stage I anal canal squamous cell carcinoma can be curativeSakti Chakrabarti, Zhaohui Jin, Brandon M Huffman, et al.
The Oncologist|July 9, 2024
Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort studyMichael H Storandt, Tyler J Zemla, Kanchi Patell, et al.
JCO Precision Oncology|January 10, 2022
Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical OutcomesGrant Wintheiser, Tyler Zemla, Qian Shi, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2015
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptorKyriakos P Papadopoulos, Randi Isaacs, Sanela Bilic, et al.
Pageof 18